In today’s recent session, 0.51 million shares of the Unicycive Therapeutics Inc (NASDAQ:UNCY) have been traded, and its beta is 2.32. Most recently the company’s share price was $0.80, and it changed around $0.0 or 0.35% from the last close, which brings the market valuation of the company to $84.32M. UNCY at last check was trading at a discount to its 52-week high of $1.82, offering almost -127.5% off that amount. The share price’s 52-week low was $0.20, which indicates that the recent value has risen by an impressive 75.0% since then. We note from Unicycive Therapeutics Inc’s average daily trading volume that its 10-day average is 1.19 million shares, with the 3-month average coming to 1.54 million.
Unicycive Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended UNCY as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Unicycive Therapeutics Inc is expected to report earnings per share of -0.07 for the current quarter.
Unicycive Therapeutics Inc (NASDAQ:UNCY) trade information
Instantly UNCY has been showing a green trend so far today with a performance of 0.35% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.8200 on recent trading dayincreased the stock’s daily price by 2.44%. The company’s shares are currently down -7.53% year-to-date, but still up 17.31% over the last five days. On the other hand, Unicycive Therapeutics Inc (NASDAQ:UNCY) is 18.37% up in the 30-day period. We can see from the shorts that 1.05 million shares have been sold at a short interest cover period of 0.74 day(s).
Unicycive Therapeutics Inc (UNCY) estimates and forecasts
Unicycive Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 48.59 percent over the past six months and at a 5.00% annual growth rate that is well below the industry average of 16.60%. The year-over-year growth rate is expected to be -100.00%, down from the previous year.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -77.09%.
UNCY Dividends
Unicycive Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
Unicycive Therapeutics Inc (NASDAQ:UNCY)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.73% of Unicycive Therapeutics Inc shares, and 38.24% of them are in the hands of institutional investors. The stock currently has a share float of 41.00%. Unicycive Therapeutics Inc stock is held by 25.0 institutions, with VIVO CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 9.9395% of the shares, which is about 3.47 million shares worth $1.74 million.
LOGOS GLOBAL MANAGEMENT LP, with 9.9389% or 3.47 million shares worth $1.74 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
